newsfilter
← Latest News
Business Wire·

Presentations at the 2023 EULAR European Congress of Rheumatology Highlight New Results from Phase 2 Trial Evaluating Dazodalibep in Sjögren's Syndrome

-- Only Sjögren's syndrome Phase 2 trial to meet the primary endpoint in both patient population types -- -- Patients with moderate-to-severe systemic disease activity (ESSDAI score ≥5) treated with dazodalibep